CHICAGO -- For patients with ventricular tachycardia (VT) and ischemic cardiomyopathy, going right to catheter ablation ...
Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...
The unlisted ingredients can cause "life threatening" drops in blood pressure when used in combination with other prescription drugs.
The unlisted ingredients can cause "life threatening" drops in blood pressure when used in combination with other prescription drugs, the agency warns.
Doctors generally hold the belief that cardiovascular disease affects more men than women, but the American Heart Association (AHA) has recently highlighted that heart disease kills more women ...
However, not everyone can have or wants to have HRT, so some symptoms can be tackled with other medications ... increase your risk for developing heart disease.” Female chimpanzees living ...
The benefits of puberty-blocking drugs for transgender children are drawing fresh attention after the scientist leading a major federally funded study was quoted by The New York Times as saying ...
The diabetes drug semaglutide, also known as Ozempic, has a positive effect on patients with chronic kidney disease and obesity ... a key measure of heart failure was reduced by 33%.
Federal officials have celebrated a striking drop in drug overdoses across the country. But state-level data shows that Black people are suffering significantly worse outcomes than white people.
Monopar Therapeutics is recovering a drug from the scrap heap of AstraZeneca’s rare disease pipeline. It has licensed ALXN-1840, a candidate for the treatment of Wilson disease that was ...
The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for widespread use in the health service in England after the health spending ...
Plus, news about In­terius Bio­Ther­a­peu­tics, Hope Med­i­cine, PMV Phar­ma­ceu­ti­cals, Epi­to­pea, Alyssum Ther­a­peu­tics and a new de­men­tia tri­al ac­cel­er­a­tor in ...